RE:RE:RE:RE:make it happenHmmm, I am the one that does not get it. Sorry if I am not dumb enough to sip the kool aid you are pouring. The thing is, in 3 years, you and your crew of promoters will say the same thing again. BTW this is way past 10 years and approaching 20 years now. I ocassionally check this stock because I still remember the cantech interview in 2014. Everyone wanted to be a believer and wanted to cash in. Okay so you are saying 3 years from now. I believe I had a bet with Cainpap from your crew, he said 6 months, 6 months ago. Lol. Anyways, whats another 3 years, it will just be another 3 years of entertainment watching how you guys work the boards. Slow day today, only one person showed up to reply to me. Forgot its the weekend, should have waited till monday when eveyone is back on pump duty. Since it is a dead board, I am out. Here is the cantech interview that just debunk your deflection abour the reason for delays. Cheers.
When do you anticipate commercialization of your cancer compounds? What do you anticipate in annual sales?
After submission and FDA approval of a Phase 1/2a clinical trial, the Company has the ability to apply to the FDA for “breakthrough status”. If Theralase is granted “breakthrough status”, then the FDA works hand-in-hand with the Company to commercialize the technology as soon as possible. In this scenario, Theralase could commercialize its anti-cancer technology as soon as early 2016. If “breakthrough status” was not granted, the Company would still qualify for “fast-track” status, which would allow the company accelerated approval status. With “fast track” approval the Company would most likely complete a Phase 2b clinical study in bladder cancer, which would allow the Company to commercialize its technology in 2017.
Why has it has taken 10 years to develop these special cancer compounds?
As with all things, I believe it takes 10 years of hard work to create an overnight success. Theralase in-licenced these PDCs ten years ago and has reviewed and tested thousands of PDCs to arrive at these four lead PDCs. The synthesis of the PDCs at the university level coupled with the in-vitro and in-vivo testing of the drugs at Princess Margaret Cancer Centre has cost millions of dollars and taken years of research to complete. Given significantly more resources in capital and personnel, the Company could have cut this timeline in half.